Faes Farma, S.A (0K9H) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Faes Farma, S.A €6.84, price €4.53, upside +50.9%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Faes Farma, S.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €2.62 – €5.28 · fair‑value band €5.19 – €8.46 · the €4.53 price screens below the €6.84 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments.
Show more
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. The company also provides animal nutrition and health products. It offers products for various therapeutic areas. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.
Stock analysis
Faes Farma, S.A (0K9H) currently trades at €4.53, while our model-based Fair Value estimate is €6.84, implying the stock looks roughly 33.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €7.88 per share, and 17 of the 25 models we run sit above the €4.53 price.
Bear case: the Asset-Based group reads lowest at €1.37, and 8 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: €5.19 (bear) to €8.46 (bull), the price of €4.53 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Faes Farma, S.A reported revenue of €380M in FY2020 versus €229M in FY2016, a compound +13.6%/yr. Reported net income was €72.5M in FY2020, compounding +18.7%/yr from FY2016.
Key figures
Market cap €1.0B · P/S ratio 1.55 · Net margin 19.1% · Return on equity 10.8% · Return on assets (EBIT) 13.9% · Operating margin 19.2% · Revenue (TTM) €674M · Revenue growth (YoY) +30.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 51%, 0K9H screens cheaper than that median.
Fair Value models
Bear €5.19Fair Value €6.84Bull €8.46
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
20.1% (2016) → 22.8% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+40.5% · Top 25%
Profitability
Return on equity (TTM)10.8% · Above median
Return on assets5.1% · Above median
Net margin (TTM)12.2% · Above median
Operating margin (TTM)19.2% · Top 25%
Growth and dividend
Revenue growth30.8% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Faes Farma, S.A (0K9H) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €6.84 versus a price of €4.53, about +51% upside (undervalued).
What is the fair value of 0K9H?
Our model-based fair value for Faes Farma, S.A is €6.84 (as of Sep 24, 2026), built from audited fundamentals. The current price: €4.53.
What is the quality score of 0K9H?
Faes Farma, S.A has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Faes Farma, S.A (0K9H)?
Our model-based price target is the fair value of €6.84 (as of Sep 24, 2026) from 25 valuation models. Cautious scenario €5.19, optimistic scenario €8.46. It is a calculation from audited fundamentals, not an analyst target.
What is the Faes Farma, S.A stock forecast for 2026?
Our models put fair value at €6.84, about +51% upside versus a price of €4.53 (undervalued). Cautious scenario €5.19, optimistic scenario €8.46. The calculation is refreshed regularly with new filings.
What is the revenue of Faes Farma, S.A (0K9H)?
Faes Farma, S.A reported trailing-twelve-month revenue of about €674M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Faes Farma, S.A (0K9H)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Faes Farma, S.A it is €6.84 per share (as of Sep 24, 2026), against a price of €4.53. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Faes Farma, S.A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0K9H trades below its calculated fair value: price €4.53, fair value €6.84, a gap of about +51% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0K9H?
No. The price is what the market pays today (€4.53); the fair value is what the company's own numbers justify (€6.84). For Faes Farma, S.A the two are €2.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Faes Farma, S.A worth?
The market values Faes Farma, S.A at about €1.0B (market capitalisation, as of Sep 24, 2026). Per share that is €4.53; our models calculate a fair value of €6.84 per share.
What do the bullish and bearish scenarios say about 0K9H?
Our models span a range for Faes Farma, S.A: cautious scenario €5.19, base €6.84, optimistic €8.46 per share (as of Sep 24, 2026, price €4.53). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Faes Farma, S.A (0K9H)?
Balance-sheet figures for Faes Farma, S.A (as of Sep 24, 2026): return on equity 10.8%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 0K9H from its 52-week high?
Faes Farma, S.A trades at €4.53, about 14% below its 52-week high of €5.28 and 7% above the low of €4.24 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €6.84 is for.
Which stocks are comparable to Faes Farma, S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Faes Farma, S.A stock attractive at the current price?
The data as of Sep 24, 2026: price €4.53, calculated fair value €6.84 (+51%), Quality Score 70/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0K9H calculated?
We run Faes Farma, S.A through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €6.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Faes Farma, S.A currently trades 34 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Faes Farma, S.A (0K9H)?
The closing price on Oct 2, 2026 was €4.53. Our model-based fair value is €6.84, about +51% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Faes Farma, S.A right now?
The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€5.19). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Faes Farma, S.A
How large is the market capitalisation of Faes Farma, S.A (0K9H)?
The market capitalisation of Faes Farma, S.A is €1.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Faes Farma, S.A (0K9H)?
The price-to-sales ratio of Faes Farma, S.A is 1.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Faes Farma, S.A (0K9H)?
The net margin of Faes Farma, S.A is 19.1% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Faes Farma, S.A (0K9H)?
The return on equity (ROE) of Faes Farma, S.A is 10.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Faes Farma, S.A (0K9H)?
On an EBIT basis the return on assets of Faes Farma, S.A is 13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Faes Farma, S.A (0K9H)?
The operating margin of Faes Farma, S.A is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Faes Farma, S.A (0K9H)?
Revenue at Faes Farma, S.A is growing +30.8% versus a year earlier (3y avg +11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Faes Farma, S.A (0K9H)?
Earnings per share at Faes Farma, S.A are growing −81.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Faes Farma, S.A in the live analysis
One click puts Faes Farma, S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
